Atherosclerosis in epilepsy: Its causes and implications

Epilepsy and Behavior

Volumn 41, Issue , 2014, Pages 290-296

  Hamed, Sherifa A ^a  

^a ASSIUT UNIVERSITY   (Egypt)

Author keywords

Age accelerated atherosclerosis; Antiepileptic drugs; Behavior; Carotid intima media thickness; Cognition; Comorbidities; Dementia; Epilepsy; Stroke

Indexed keywords

AGE; ALZHEIMER DISEASE; ARTERIAL WALL THICKNESS; BEHAVIOR CHANGE; BRAIN ATHEROSCLEROSIS; BRAIN ATROPHY; COGNITION; COMMON CAROTID ARTERY; COMORBIDITY; EPILEPSY; HIPPOCAMPUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERINSULINEMIA; HYPERURICEMIA; INSULIN RESISTANCE; INTERNAL CAROTID ARTERY; MESIAL TEMPORAL LOBE EPILEPSY; MULTIINFARCT DEMENTIA; OBESITY; OXIDATIVE STRESS; PATIENT MONITORING; REVIEW; RISK FACTOR; ATHEROSCLEROSIS; COGNITION DISORDERS;

ATHEROSCLEROSIS; COGNITION DISORDERS; COMORBIDITY; EPILEPSY; HUMANS;

EID: 84918576899     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2014.07.003     Document Type: Review

References (143)

1. Reynolds E.H. The ILAE/IBE/WHO Global Campaign against Epilepsy: bringing epilepsy "out of the shadows". Epilepsy Behav 2000, 1:S3-S8.
2. Osuntoku B.O. Epilepsy in the African continent. The eighth international symposium 1977, 365-378. Raven Press, New York. J.K. Peny (Ed.).
3. Hauser W.A. Incidence and prevalence. Epilepsy: a comprehensive textbook 1997, 47-57. Lippincott-Raven, Philadelphia. J. Engel, T.A. Pedley (Eds.).
4. Aldenkamp A.P., Bodde N. Behaviour, cognition and epilepsy. Acta Neurol Scand 2005, 112:S19-S25.
5. Piazzini A., Canevini M.P., Turner K., Chifari R., Canger R. Elderly people and epilepsy: cognitive function. Epilepsia 2006, 47:82-84.
6. Hermann B., Seidenberg M., Jones J. The neurobehavioural comorbidities of epilepsy: can a natural history be developed?. Lancet Neurol 2008, 7:151-160.
7. Hamed S.A. The aspects and mechanisms of cognitive alterations in epilepsy: the role of antiepileptic medications. CNS Neurosci Ther 2009, 15:134-156.
8. Jones J.E., Hermann B.P., Barry J.J., Gilliam F.G., Kanner A.M., Meador K.J. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav 2003, 4:S31-S38.
9. Endermann M., Zimmermann F. Factors associated with health-related quality of life, anxiety and depression among young adults with epilepsy and mild cognitive impairments in short-term residential care. Seizure 2009, 18:167-175.
10. Hamed S.A., Metwaly N.A., Hassan M.M., Mohamed K.A., Ahmad M.A., Soliman A.A., et al. Depression in adults with epilepsy: relationship to psychobiological variables. World J Neurol 2012, 2(1):1-10.
11. Hamed S.A., Elserogy Y.E., Abdou M.A., Abdellah M.M. The risks of suicidality in adult patients with epilepsy. World J Psychiatry 2012, 2:33-42.
12. Hamed S.A., Elserogy Y.E., Abd-ElHafeez H.A. Psychopathological and peripheral level of neurobiological correlates of obsessive compulsive symptoms with epilepsy: a hospital-based study. Epilepsy Behav 2013, 27:409-415.
13. Gaitatzis A., Sisodiya S.M., Sander J.W. The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia 2012, 53:1282-1293.
14. Apeland T., Mansoor M.A., Strandjord R.E. Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res 2001, 47:27-35.
15. Sener U., Zorlu Y., Karaguzel O., Ozdamar O., Coker I., Topbas M. Effect of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6. Seizure 2006, 15:79-85.
16. Hamed S.A., Nabeshima T. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. J Pharmacol Sci 2005, 98:340-353.
17. Hamed S.A., Hamed E.A., Hamdy R., Nabeshima T. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res 2007, 74:183-192.
18. Calandre E.P., Rodriquez-Lopez C., Blazquez A., Cano D. Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand 1991, 83:250-253.
19. Eris J., Novo-Rodriguez M.I., Del Rio M., Meseguer P., Del Rio M.C., Castro-Gago M. The effects on lipid and apolipoprotein on serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res 2000, 41:1-7.
20. Schwaninger M., Ringleb P., Annecke A., Winter R., Kohl B., Werle E., et al. Elevated plasma concentrations of lipoprotein(a) in medicated epileptic patients. J Neurol 2000, 247:687-690.
21. Voudris K.A., Attilakos A., Katsarou E., Drakatos A., Dimou S., Mastroyianni S., et al. Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res 2006, 70:211-217.
22. Kim D.W., Lee S.Y., Shon Y.M., Kim J.H. Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy. Epilepsia 2013, 54:e146-e149.
23. Isojarvi J.I., Laatikainen T.J., Knip M., Pakarinen A.J., Juntunen K.T., Myllyla V.V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996, 39:579-584.
24. Pylvanen V., Pakarinen A., Knip M., Isojarvi J. Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia 2006, 47:1460-1464.
25. Hamed S.A. Leptin and insulin homeostasis in epilepsy: relation to weight adverse conditions. Epilepsy Res 2007, 75:1-9.
26. Hamed S.A., Fida N.M., Hamed E.A. States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. Eur J Pediatr Neurol 2009, 13:261-268.
27. Isojärvi J.I., Turkka J., Pakarinen A.J., Kotila M., Rättyä J., Myllylä V.V. Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia 2001, 42:930-934.
28. Verrotti A., Basciani F., Morresi S., Morgese G., Chiarelli F. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatr Neurol 2001, 25:43-46.
29. Hamed S.A., Hamed E.A., Kandil M.R., El-Shereef H.K., Abdellah M.M., Omar H. Serum thyroid hormone balance and lipid profile in patients with epilepsy. Epilepsy Res 2005, 66:173-183.
30. Hamed S.A., Abdellah M.M., El-Melegy N.T. Blood levels of trace elements, electrolytes and oxidative stress/antioxidant systems in epileptic patients. J Pharmacol Sci 2004, 96:465-473.
31. Mintzer S., Skidmore C.T., Abidin C.J., Morales M.C., Chervoneva I., Capuzzi D.M., et al. Effects of antiepileptic drugs on lipids, homocysteine, and C reactive protein. Ann Neurol 2009, 65:448-456.
32. Chuang Y.C., Chuang H.Y., Lin T.K., Chang C.C., Lu C.H., Chang W.N., et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 2012, 53:120-128.
33. Verrotti A., Scardapane A., Franzoni E., Manco R., Chiarelli F. Increased oxidative stress in epileptic children treated with valproic acid. Epilepsy Res 2008, 78:171-177.
34. de Chadarevian J.P., Legido A., Miles D.K., Katsetos C.D. Epilepsy, atherosclerosis, myocardial infarction, and carbamazepine. J Child Neurol 2003, 18:150-151.
35. Erdemir A., Cullu N., Yiş U., Demircioğlu F., Kir M., Cakmakçi H., et al. Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev 2009, 31:713-716.
36. Tan T.Y., Lu C.H., Chuang H.Y., Lin T.K., Liou C.W., Chang W.N., et al. Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia 2009, 50:1579-1586.
37. Yildiz M., Simsek G., Uzun H., Uysal S., Sahin S., Balci H. Assessment of low-density lipoprotein oxidation, paraoxonase activity, and arterial distensibility in epileptic children who were treated with anti-epileptic drugs. Cardiol Young 2010, 20:547-554.
38. Tokgoz H., Aydin K., Oran B., Kiyici A. Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate. Childs Nerv Syst 2012, 28:1049-1053.
39. Sankhyan N., Gulati S., Hari S., Kabra M., Ramakrishnan L., Kalra V. Noninvasive screening for preclinical atherosclerosis in children on phenytoin or carbamazepine monotherapy: a cross sectional study. Epilepsy Res 2013, 107:121-126.
40. Annegers J.F., Hauser W.A., Shirts S.B. Heart disease mortality and morbidity in patients with epilepsy. Epilepsia 1984, 25:699-704.
41. Muuronen A., Kaste M., Nikkila E.A., Tolppanen E.M. Mortality from ischemic heart disease among the patients using anticonvulsive drugs: a case-control study. BMJ 1985, 291:1481-1483.
42. Lhatoo S.D., Johnson A.L., Goodridge D.M., MacDonald B.K., Sander J.W., Shorvon S.D. Mortality in epilepsy in the first 11 to 14years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. Ann Neurol 2001, 49:336-344.
43. Hsieh C.Y., Lai E.C., Yang Y.H., Lin S.J. Comparative stroke risk of antiepileptic drugs in patients with epilepsy. Epilepsia 2013, 54:172-180.
44. Cleary P., Shorvon S., Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet 2004, 363:1184-1186.
45. Chang C.S., Liao C.H., Lin C.C., Lane H.Y., Sung F.C., Kao C.H. Patients with epilepsy are at an increased risk of subsequent stroke: a population-based cohort study. Seizure 2014, 10.1016/j.seizure.2014.02.007.
46. Lin J.J., Mula M., Hermann B.P. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 2012, 380:1180-1192.
47. Martin R., Vogtle L., Gilliam F., Faught E. What are the concerns of older adults living with epilepsy?. Epilepsy Behav 2005, 7:297-300.
48. Knopman D., Boland L.L., Mosley T., Howard G., Liao D., Szklo M., et al. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001, 56:42-48.
49. Wendell C.R., Zonderman A.B., Metter E.J., Najjar S.S., Waldstein S.R. Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke 2009, 40:3180-3185.
50. Haley A.P., Tarumi T., Gonzales M.M., Sugawara J., Tanaka H. Subclinical atherosclerosis is related to lower neuronal viability in middle-aged adults: a 1H MRS study. Brain Res 2010, 1344:54-61.
51. Romero J.R., Beiser A., Seshadri S., Benjamin E.J., Polak J.F., Vasan R.S., et al. Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. Stroke 2009, 40:1590-1596.
52. Sander K., Bickel H., Förstl H., Etgen T., Briesenick C., Poppert H., et al. Carotid- intima media thickness is independently associated with cognitive decline. The INVADE study. Int J Geriatr Psychiatry 2010, 25:389-394.
53. Mathiesen E.B., Waterloo K., Joakimsen O., Bakke S.J., Jacobsen E.A., Bonaa K.H. Reduced neuropsychological test performance in asymptomatic carotid stenosis: the Tromso study. Neurology 2004, 62:695-701.
54. Smith P.J., Blumenthal J.A., Babyak M.A., Hoffman B.M., Doraiswamy P.M., Waugh R., et al. Cerebrovascular risk factors, vascular disease, and neuropsychological outcomes in adults with major depression. Psychosom Med 2007, 69:578-586.
55. van Oijen M., de Jong F.J., Witteman J.C., Hofman A., Koudstaal P.J., Breteler M.M. Atherosclerosis and risk for dementia. Ann Neurol 2007, 61:403-410.
56. Manolio T.A., Burke G.L., O'Leary D.H., Evans G., Beauchamp N., Knepper L., et al. Relationships of cerebral MRI findings to ultrasonographic carotid atherosclerosis in older adults: the cardiovascular health study. CHS collaborative research group. Arterioscler Thromb Vasc Biol 1999, 19:356-365.
57. Dubois M.F., Hebert R. The incidence of vascular dementia in Canada: a comparison with Europe and East Asia. Neuroepidemiology 2001, 20:179-187.
58. Dufouil C., Alperovitch A., Ducros V., Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol 2003, 53:214-221.
59. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002, 346:476-483.
60. Panza F., D'Introno A., Colacicco A.M., Capurso C., Pichichero G., Capurso S.A., et al. Lipid metabolism in cognitive decline and dementia. Brain Res Brain Res Rev 2006, 51:275-292.
61. Greenwood C.E., Winocur G. High-fat diets, insulin resistance and declining cognitive function. Neurobiol Aging 2005, 26:42-45.
62. Young S.E., Mainous A.G., Carnemolla M. Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care 2006, 29:2688-2693.
63. Zhu D.F., Wang Z.X., Zhang D.R., Pan Z.L., He S., Hu X.P., et al. fMRI revealed neural substrate for reversible working memory dysfunction in subclinical hypothyroidism. Brain 2006, 129:2923-2930.
64. Resta F., Triggiani V., Barile G., Benigno M., Suppressa P., Giagulli V.A., et al. Subclinical hypothyroidism and cognitive dysfunction in the elderly. Endocr Metab Immune Disord Drug Targets 2012, 12:260-267.
65. Aghili R., Khamseh M.E., Malek M., Hadian A., Baradaran H.R., Najafi L., et al. Changes of subtests of Wechsler Memory Scale and cognitive function in subjects with subclinical hypothyroidism following treatment with levothyroxine. Arch Med Sci 2012, 8:1096-1101.
66. Tay S.Y., Ampil E.R., Chen C.P.L.H., Auchus A.P. The relationship between homocysteine, cognition and stroke subtypes in acute stroke. J Neurol Sci 2006, 250:58-61.
67. Blasko I., Hinterberger M., Kemmler G., Jungwirth S., Krampla W., Leitha T., et al. Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort. J Nutr Health Aging 2012, 16:687-694.
68. Hassing L.B., Dahl A.K., Thorvaldsson V., Berg S., Gatz M., Pedersen N.L., et al. Overweight in midlife and risk of dementia: a 40-year follow up study. Int J Obes (Lond) 2009, 33:893-898.
69. Mueller K., Sacher J., Arelin K., Holiga S., Kratzsch J., Villringer A., et al. Overweight and obesity are associated with neuronal injury in the human cerebellum and hippocampus in young adults: a combined MRI, serum marker and gene expression study. Transl Psychiatry 2012, 2:e200.
70. Marqués-Iturria I., Pueyo R., Garolera M., Segura B., Junqué C., García-García I., et al. Frontal cortical thinning and subcortical volume reductions in early adulthood obesity. Psychiatry Res 2013, 214:109-115.
71. Shinton R.A., Gill J.S., Zezulka A.V., Beevers D.G. The frequency of epilepsy preceding stroke. Case-control study in 230 patients. Lancet 1987, 1:11-13.
72. Ubbink J.B., Becker P.J., Vermaak W.J.H., Del Ponte R. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine. Clin Chem 1995, 41:1033-1037.
73. Kishi T., Fujita N., Eguchi T., Ueda K. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997, 145:109-112.
74. Vilaseca M.A., Monros E., Artuch R., Colome C., Farre C., Valls C., et al. Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C->T mutation of the methylenetetrahydrofolate reductase gene. Eur J Paediatr Neurol 2000, 4:269-277.
75. Verrotti A., Pascarella R., Trotta D., Giuva T., Morgese G., Chiarelli F. Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res 2000, 41:253-257.
76. Wegner C., Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology 1992, 42:17-24.
77. Hogervorst E., Ribiero H.M., Molyneux A., Budge M., Smith D. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002, 59:787-793.
78. Tanne D., Haim M., Goldbourt U., Boyko V., Doolman R., Adler Y., et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 2003, 34:632-636.
79. Kloppenborg R.P., Nederkoorn P.J., van der Graaf Y., Geerlings M.I. Homocysteine and cerebral small vessel disease in patients with symptomatic atherosclerotic disease. The SMART-MR study. Atherosclerosis 2011, 216:461-466.
80. Stein J.H., McBride P.E. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening and treatment. Arch Intern Med 1998, 158:1301-1306.
81. Thambyrajah J., Townend J.N. Homocysteine and atherothrombosis - mechanisms for injury. Eur Heart J 2000, 21:967-974.
82. Schroecksnadel K., Frick B., Wirleitner B., Winkler C., Schennach H., Fuchs D. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004, 5:107-118.
83. Yamamoto M., Hara H., Adachi T. Effects of homocysteine on the binding of extracellular-superoxide dismutase to the endothelial cell surface. FEBS Lett 2000, 486:159-162.
84. Riba R., Nicolaou A., Troxler M., Homer-Vaniasinkam S., Naseem K.M. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis 2004, 175:69-75.
85. Harpel P.C., Chang V.T., Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A 1992, 89:10193-10197.
86. Sauls D.L., Wolberg A.S., Hoffman M. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost 2003, 1:300-306.
87. Aggarwal A., Singh V., Batra S., Faridi M.M., Sharma S. Effect of carbamazepine therapy on serum lipids in children with partial epilepsy. Pediatr Neurol 2009, 40:94-97.
88. Isojärvi J.I., Pakarinen A.J., Rautio A., Pelkonen O., Myllylä V.V. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxacarbazepine. Epilepsia 1994, 35:1217-1220.
89. Eirís J., Novo-Rodríguez M.I., Del Río M., Meseguer P., Del Río M.C., Castro-Gago M. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res 2000, 41(1):1-7.
90. Nikolaos T., Stylianos G., Chryssoula N., Irini P., Christos M., Dimitrios T., et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 2004, 10:50-52.
91. Nebert D.W., Russell D.W. Clinical importance of the cytochromes P450. Lancet 2002, 360:1155-1162.
92. Luoma P.V., Myllyla V.V., Sotaniemi E.A., Lehtinen I.A., Hokkanen E.J. Plasma high-density lipoprotein cholesterol in epileptics treated with various anticonvulsants. Eur Neurol 1980, 19:67-72.
93. Domingo N., Mastellone I., Gres S., Marin V., Lorec A.M., Tosini F., et al. The endothelial cholesterol efflux is promoted by the high density lipoprotein anionic peptide factor. Metabolism 2005, 58:1087-1094.
94. Fielding P.E., Fielding C.J., Havel R.J., Kane J.P., Tun P. Cholesterol net transport, esterification, and transfer in human hyperlipidemic plasma. J Clin Invest 1983, 71:449-460.
95. Kondo A., Li J., Manabe M., Saito K., Kanno T., Maekawa M. Relationship between high-density lipoprotein-cholesterol and malondialdehyde modified low-density lipoprotein concentrations. J Atheroscler Thromb 2003, 10:72-78.
96. Easter D., O'Brvan-Tear C.G., Verity C. Weight gain with valproate or carbamazepine - a reappraisal. Seizure 1997, 6:121-125.
97. Maggioni F., Ruffatti S., Dainese F., Mainardi F., Zanchin G. Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. J Headache Pain 2005, 6:322-324.
98. Drieling T., Biedermann N.C., Scharer L.O., Strobi N., Langosch J.M. Psychotropic drug-induced changes of weight: a review. Fortschr Neurol Psychiatr 2007, 75:65-80.
99. Arroy S., Anhut T., Kugler A.R., Lee C.M., Knapp L.E., Garofalo E.A., et al. Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose response study in adults with partial seizures. Epilepsia 2004, 45:20-27.
100. Novak G.P., Maytal J., Alshansky A., Eviatar L., Sy-Kho R., Siddique Q. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999, 14:490-495.
101. Pylvanen V., Knip M., Pakarinen A., Kotila M., Turkka J., Isojarvi J.I. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002, 43:514-517.
102. Richens A., Davidson D.L., Cartlidge N.E., Easter D.J. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG collaborative group. J Neurol Neurosurg Psychiatry 1994, 57:765-771.
103. Janousek J., Barber A., Goldman L., Klein P. Obesity in adults with epilepsy. Epilepsy Behav 2013, 28:391-394.
104. Irace C., Scavelli F., Carallo C., Serra R., Cortese C., Gnasso A. Body mass index, metabolic syndrome and carotid atherosclerosis. Coron Artery Dis 2009, 20:94-99.
105. Duntas L.H., Wartofsky L. Cardiovascular risk and subclinical hypothyroidism: focus on lipids and new emerging risk factors. What is the evidence?. Thyroid 2007, 17:1057-1084.
106. Huesca-Gómez C., Franco M., Luc G., Montaño L.F., Massó F., Posadas-Romero C., et al. Chronic hypothyroidism induces abnormal structure of high-density lipoproteins and impaired kinetics of apolipoprotein A-I in the rat. Metabolism 2002, 51:443-550.
107. Spacilova J., Limanova Z., Aschermann M. Subclinical hypothyroidism with emphasis on the cardiovascular system. Cas Lek Cesk 2003, 142:643-647.
108. Maesaka J.K., Fishban S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998, 32:917-933.
109. Kanellis J., Kang D.H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005, 25:39-42.
110. Patterson R.A., Horsley E.T., Leake D.S. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res 2003, 44:512-521.
111. Culleton B.F., Larson M.G., Kannel W.B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999, 131:7-13.
112. de la Torre J.C. Critically attained threshold of cerebral hypoperfusion: can it cause Alzheimer's disease?. Ann N Y Acad Sci 2000, 903:424-436.
113. Dede D.S., Yavuz B., Yavuz B.B., Cankurtaran M., Halil M., Ulger Z., et al. Assessment of endothelial function in Alzheimer's disease: is Alzheimer's disease a vascular disease?. J Am Geriatr Soc 2007, 55:1613-1617.
114. Sparks D.L., Scheff S.W., Hunsaker J.C., Liu H., Landers T., Gross D.R. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994, 126:88-94.
115. Miklossy J. Cerebral hypoperfusion induces cortical watershed microinfarcts which may further aggravate cognitive decline in Alzheimer's disease. Neurol Res 2003, 25:605-610.
116. Bell R.D., Zlokovic B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009, 118:103-113.
117. Zhang C.E., Tian Q., Wei W., Peng J.H., Liu G.P., Zhou X.W., et al. Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 2008, 29:1654-1665.
118. Umeda T., Tomiyama T., Kitajima E., Idomoto T., Nomura S., Lambert M.P., et al. Hypercholesterolemia accelerates intraneuronal accumulation of Aβ oligomers resulting in memory impairment in Alzheimer's disease model mice. Life Sci 2012, 91:1169-1176.
119. Kuusisto J., Koivisto K., Mykkänen L., Helkala E.L., Vanhanen M., Hänninen T., et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype. BMJ 1997, 315:1045-1049.
120. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012, 122:1316-1338.
121. Fishel M.A., Watson G.S., Montine T.J., Wang Q., Green P.S., Kulstad J.J., et al. Hyperinsulinemia provokes synchronous increases in central inflammation and amyloid in normal adults. Arch Neurol 2005, 62:1539-1544.
122. Hamed S.A., Abd Elaal R.F., Mohamad K.A., Youssef A.H., Abdou M.A. Neuropsychological, neurophysiological and laboratory markers of direct brain injury in type 2 diabetes mellitus. J Neurol Neurosci 2012, 3:2. 10.3823/326.
123. Kruman I.I., Culmsee C., Chan S.L., Kruman Y., Guo Z., Penix L., et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000, 20:6920-6936.
124. Langmeier M., Folbergrova J., Haugvicova R., Pokorny J., Mares P. Neuronal cell death in hippocampus induced by homocysteic acid in immature rats. Epilepsia 2003, 44:299-304.
125. Cramer C., Haan M.N., Galea S., Langa K.M., Kalbfleisch J.D. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008, 71:344-350.
126. Ullrich C., Pirchl M., Humpel C. Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 2010, 45:408-417.
127. Debette S., Beiser A., Hoffmann U., Decarli C., O'Donnell C.J., Massaro J.M., et al. Visceral fat is associated with lower brain volume in healthy middle-aged adults. Ann Neurol 2010, 68:136-144.
128. Harvey J., Shanley L.J., O'Malley D., Irving A.J. Leptin: a potential cognitive enhancer?. Biochem Soc Trans 2005, 33:1029-1032.
129. Facchini F.S., Hua N., Abbasi F., Reaven G.M. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001, 86:3574-3578.
130. Chiu S., Chen C., Cline H. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 2008, 58:708-719.
131. Hamed S.A., Youssef A.H., Elserogy Y.E., Herdan O., Abd-Elaal R.F., Metwaly N.A., et al. Cognitive function in patients with type 2 diabetes mellitus: relationship to stress hormone (cortisol). J Neurol Neurosci 2013, 4:3. 10.3823/335.
132. Adeghate E., Donath T., Adem A. Alzheimer disease and diabetes mellitus: do they have anything in common?. Curr Alzheimer Res 2013, 10:609-617.
133. Bernard C., Helmer C., Dilharreguy B., Amieva H., Auriacombe S., Dartigues J.F., et al. Time course of brain volume changes in the preclinical phase of Alzheimer's disease. Alzheimers Dement 2014, 10:143-151.
134. Hermann B., Seidenberg M., Bell B., Rutecki P., Sheth R.D., Wendt G., et al. Extratemporal quantitative MR volumetrics and neuropsychological status in temporal lobe epilepsy. J Int Neuropsychol Soc 2003, 9:353-362.
135. Natsume J., Bernasconi N., Andermann F., Bernasconi A. MRI volumetry of the thalamus in temporal, extratemporal, and idiopathic generalized epilepsy. Neurology 2003, 60:1296-1300.
136. Briellmann R.S., Wellard R.M., Jackson G.D. Seizure-associated abnormalities in epilepsy: evidence from MR imaging. Epilepsia 2005, 46:760-766.
137. Kövari E., Herrmann F.R., Hof P.R., Bouras C. The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer's disease. Neuropathol Appl Neurobiol 2013, 39:498-509.
138. Radhakrishnan A., Radhakrishnan K., Radhakrishnan V.V., Mary P.R., Kesavadas C., Alexander A., et al. Corpora amylacea in mesial temporal lobe epilepsy: clinico-pathological correlations. Epilepsy Res 2007, 74:81-90.
139. Ben-Menachem E., Axelsen M., Johanson E.H., Stagge A., Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003, 11:556-562.
140. Kim D.W., Yoo M.W., Park K.S. Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. Epilepsy Behav 2012, 23:497-499.
141. Pugh M.J., Knoefel J.E., Mortensen E.M., Amuan M.E., Berlowitz D.R., Van Cott A.C. New-onset epilepsy risk factors in older veterans. J Am Geriatr Soc 2009, 57:237-242.
142. Etminan M., Samii A., Brophy J.M. Statin use and risk of epilepsy: a nested case-control study. Neurology 2010, 75:1496-1500.
143. Hankey G.J., Ford A.H., Yi Q., Eikelboom J.W., Lees K.R., Chen C., et al. Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis. Stroke 2013, 44:2232-2239.